Results 1 to 10 of about 13,754 (143)

Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial [PDF]

Scientific Reports
To compare the efficacy of topical caspofungin 0.5% with topical voriconazole 1% in patients with fungal keratitis. In this pilot clinical trial, thirty-four eyes from 34 patients diagnosed with fungal keratitis, confirmed by positive smear or culture ...
Mehrnaz Atighehchian, Golshan Latifi, Ahmed Shalaby Bardan, Dean Ouano, Siamak Zarei-Ghanavati, Zohreh Abedinifar, Mehran Zarei-Ghanavati   +6 more
doaj   +2 more sources

In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method

International Journal of Infectious Diseases, 2022
Objectives: Increased resistance of Candida species, especially Candida. glabrata is problematic. Combination antifungal therapies were studied to solve the problem.
Qianting Yang, Zhiyong Liu, Yan Wang, Jiao Xie, Kanghuai Zhang, Yalin Dong, Yun F. Wang   +6 more
doaj   +1 more source

Assessment of Caspofungin use at a Tertiary Teaching Hospital and compliance with IDSA guidelines and FDA labelings

Saudi Pharmaceutical Journal, 2022
Objective: The aim of this study is to evaluate the utilization pattern of Caspofungin in an academic tertiary care hospital in Riyadh, Saudi Arabia. Methods: This is a retrospective study, conducted at King Saud University Medical City, Riyadh, Saudi ...
Abrar F. Alshehri, Thamer A. Almangour, Abdullah A. Alhifany, Abdulaziz Alhossan   +3 more
doaj   +1 more source

Synergistic Activity of the Human Lactoferricin-Derived Peptide hLF1-11 in Combination with Caspofungin against Candida Species

Microbiology Spectrum, 2022
Candida species are the main fungal opportunistic pathogens causing systemic infections that are often associated with drug resistance and biofilm production on medical devices.
Roberta Fais, Cosmeri Rizzato, Iacopo Franconi, Arianna Tavanti, Antonella Lupetti   +4 more
doaj   +1 more source

Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Emergence of Candida species resistant to Amphotericin B and triazole has led to use of echinocandins, mostly caspofungin in the management of invasive candidiasis.
Shashir Wanjare, Rajarshi Gupta, Preeti Mehta   +2 more
doaj   +1 more source

Caspofungin [PDF]

Clinical Infectious Diseases, 2003
Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and ...
Louis D. Saravolatz, Stanley C. Deresinski, David A. Stevens   +2 more
openaire   +2 more sources

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. [PDF]

PLoS ONE, 2013
Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for ...
Maria Luísa Lobo, Francisco Esteves, Bruno de Sousa, Fernando Cardoso, Melanie T Cushion, Francisco Antunes, Olga Matos   +6 more
doaj   +1 more source

Membrane Integrity Contributes to Resistance of Cryptococcus neoformans to the Cell Wall Inhibitor Caspofungin

mSphere, 2022
The fungal pathogen Cryptococcus neoformans causes up to 278 000 infections each year globally, resulting in up to 180,000 deaths annually, mostly impacting immunocompromised people. Therapeutic options for C.
Brenda Moreira-Walsh, Abigail Ragsdale, Woei Lam, Rajendra Upadhya, Evan Xu, Jennifer K. Lodge, Maureen J. Donlin   +6 more
doaj   +1 more source

Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Effective antifungal therapy is important to reduce mortality in patients with invasive fungal infections (IFIs). Numerous factors affect pharmacokinetic/pharmacodynamic (PK/PD) parameters in critically-ill patients.
Fangyi Li, Minggen Zhou, Zheng Jiao, Zijun Zou, Erqian Yu, Zhijie He   +5 more
doaj   +1 more source

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia

BMC Health Services Research, 2022
Background Invasive candidiasis and/or candidemia (IC/C) is a common fungal infection leading to significant health and economic losses worldwide. Caspofungin was shown to be more effective than fluconazole in treating inpatients with IC/C. However, cost-
Gebremedhin Beedemariam Gebretekle, Atalay Mulu Fentie, Girma Tekle Gebremariam, Eskinder Eshetu Ali, Daniel Asfaw Erku, Tinsae Alemayehu, Workeabeba Abebe, Beate Sander   +7 more
doaj   +1 more source